Literature DB >> 20712575

Interleukin 2 in cancer therapy.

G K Antony1, A Z Dudek.   

Abstract

Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20712575     DOI： 10.2174/092986710793176410

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  37 in total

Review 1.  Immunotherapy for head and neck cancer: advances and deficiencies.

Authors:  Anna-Maria De Costa; M Rita I Young
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

Review 2.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

Review 3.  Immunotherapy for ovarian cancer.

Authors:  Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel
Journal:  Curr Treat Options Oncol       Date:  2015-01

Review 4.  Opposing functions of IL-2 and IL-7 in the regulation of immune responses.

Authors:  Shoshana D Katzman; Katrina K Hoyer; Hans Dooms; Iris K Gratz; Michael D Rosenblum; Jonathan S Paw; Sara H Isakson; Abul K Abbas
Journal:  Cytokine       Date:  2011-07-31       Impact factor: 3.861

Review 5.  The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Authors:  Gregory K Pennock; Laura Q M Chow
Journal:  Oncologist       Date:  2015-06-11

6.  Inter-donor variation in cell subset specific immune signaling responses in healthy individuals.

Authors:  Diane M Longo; Brent Louie; Ena Wang; Zoltan Pos; Francesco M Marincola; Rachael E Hawtin; Alessandra Cesano
Journal:  Am J Clin Exp Immunol       Date:  2012-04-24

Review 7.  Immunogenicity and other problems associated with the use of biopharmaceuticals.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Ther Adv Drug Saf       Date:  2011-06

8.  IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

Authors:  H J Pegram; T J Purdon; D G van Leeuwen; K J Curran; S A Giralt; J N Barker; R J Brentjens
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

9.  Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.

Authors:  Soyoung Baek; Yong-Man Kim; Sung-Bae Kim; Choung-Soo Kim; Seog-Woon Kwon; YongMan Kim; HyunSoo Kim; Hyunah Lee
Journal:  Cell Mol Immunol       Date:  2014-06-30       Impact factor: 11.530

10.  Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.